• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals Presents at American Diabetes Association's 83rd Scientific Sessions: Advancing Global Efforts in Diabetes Prevention and Control
    Gan & Lee Pharmaceuticals Presents at American Diabetes Association's 83rd Scientific Sessions: Advancing Global Efforts in Diabetes Prevention and Control
    Date:2023-06-28

    American Diabetes Association's 83rd Scientific Sessions recently concluded at the San Diego Conference Center in San Diego, California, USA, held from June 23-26, 2023. As one of the largest diabetes conferences globally, the conference drew over 12,000 esteemed physicians, scientists, and healthcare professionals from various parts of the world. This significant event showcased cutting-edge scientific breakthroughs in the diabetes field, encompassing more than 90 scientific sessions and featuring over 2,000 original research presentations1.


    Throughout the exhibition, Gan & Lee Pharmaceuticals' booth attracted experts, scholars, media representatives, doctors, and individuals associated with the diabetes field from various countries. This engagement helped enhance industry insiders' comprehension of Gan & Lee's current standing. One attendee expressed his delight, stating, "I am pleased to witness Gan & Lee's enduring dedication and profound commitment to the diabetes field. It is gratifying to see a Chinese company taking the stage at ADA to represent the voice of China.”


    In the medical information area, Gan & Lee's team prominently showcased the company's drug pipeline for the international market. The team also provided insights into the published clinical data that supports the company's Biologics License Application (BLA) at US FDA, thus laying a favorable and efficient groundwork for the subsequent launch of relevant products in the United States.


    Gan & Lee's insulin and device products have been launched in nearly 20 countries spanning four continents. Notably, this year, the company has received BLA acceptance from the U.S. FDA on its three core products – Insulin Glargine, Lispro, and Aspart. The three BLAs have entered the substantive review stage, and Gan & Lee will do their best to facilitate the approval in the U.S. and Europe. By actively expanding the product reach into diverse global markets, Gan & Lee strongly believes in fostering strong connections with the global diabetes community and extending the benefits of their products to a greater number of patients worldwide.


    References:

    1.American Diabetes Association. (2023, June 19). The American Diabetes Association commences its 83rd scientific sessions to showcase game changing diabetes advances. The American Diabetes Association Commences its 83rd Scientific Sessions to Showcase Game Changing Diabetes Advances | ADA. https://diabetes.org/newsroom/press-releases/2023/american-diabetes-association-commences-83rd-scientific-sessions-showcase-diabetes-advances


    About Gan & Lee

    Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. 




    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網安備 11011202003900號
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 国产福利在线小视频| 免费五级在线观看日本片| 亚洲黄色在线观看视频| 亚洲精品视频免费看| 久久久国产精品无码免费专区| 97视频免费在线| 羞羞视频在线观看网站| 精品视频在线观看一区二区| 最近韩国电影免费高清播放在线观看 | 福利片一区二区| 日本精品a在线| 国产精品无码无卡无需播放器| 免费特级黄毛片| 中文字幕一区二区三区乱码| 成人免费黄色网址| 欧美成人免费公开播放欧美成人免费一区在线播放 | 日本妇乱子伦视频| 国产精品k频道在线看| 亚洲精品国产福利一二区| 一本一本久久a久久精品综合麻豆 一本一本久久a久久精品综合麻豆 | 怡红院亚洲色图| 国产亚洲欧美一区二区三区| 亚洲av中文无码乱人伦| 91精品免费在线观看| 男女之间差差差| 尤物国产精品福利三区| 国产一区二区精品在线观看| 久久毛片免费看一区二区三区| 亚洲xxxx18| 欧美三级在线看中文字幕 | 国产v亚洲v欧美v专区| 久久天堂成人影院| 麻豆国产精品一二三在线观看| 欧美伊香蕉久久综合类网站| 国产香蕉视频在线播放| 人人鲁人人莫人人爱精品| 5566中文字幕| 欧美成人亚洲高清在线观看| 国产成人综合精品| 久久综合九九亚洲一区| 高h黄全肉一女n男古风|